Pharmaceutical inventions: when is the granting of a patent justified?
by Carlos M. Correa
International Journal of Intellectual Property Management (IJIPM), Vol. 1, No. 1/2, 2006

Abstract: The paper elaborates on the leeway left by the Agreement on Trade Related Aspects of Intellectual Property Rights to determine how the patentability requirements are applied, particularly for pharmaceuticals. In addition to claims on the active ingredients as such, numerous patents are applied in relation to pharmaceutical formulations, compositions, combinations, dosage forms, salts, polymorphs, optical isomers, metabolites, etc. Often claims encompass large families of compounds while 'selection patents' cover a sub-group of previously disclosed compounds. The paper also briefly considers the case of second pharmaceutical indications. It contains some recommendations to handle these issues, taking public health interests into account.

Online publication date: Tue, 03-Oct-2006

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Intellectual Property Management (IJIPM):
Login with your Inderscience username and password:

    Username:        Password:         

Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email